Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P89 is a human processed pseudogene, meaning it is a non-functional DNA sequence similar to the parental ribosomal protein L21 gene. Unlike the protein-coding RPL21 gene, RPL21P89 does not encode an active protein and has no known functional roles in the cell. Pseudogenes like RPL21P89 are dispersed throughout the genome as remnants of gene duplication or retrotransposition events, and do not serve a direct purpose in normal biology or disease. This pseudogene is not utilized as a therapeutic target or biomarker, and there are no known drugs or disease associations specific to RPL21P89[2][7]. RPL21P89 is not a functional receptor or enzyme and is not considered a drug target. It is a pseudogene designated for genomic cataloging but of no clinical or research significance as a molecular target. This makes it an incorrect or irrelevant entry for drug targeting or molecular classification purposes[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 89 (RPL21P89).